|
1.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T (St István and St László Hospital of Budapest) ;
Petrucci,M.T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K.L. (University College London Cancer Institute) ;
Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ;
Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ;
Pour, L (University Hospital Ostrava) ;
Dimopoulos, M.A. (National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ;
Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Hospital Elisabethinen Linz) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (Southampton General Hospital, Hampshire, UK) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, J. (Hospital Universitario La Fe, València) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, X. (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA) ;
Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 -  10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
